TGFB1 and melanoma: In the xenograft setup, the MEKi-resistant melanoma cell line was injected subcutaneously, and tumors were allowed to grow to approximately 300 mm3 before initiating three intra-tumoral injections of TGFβ1 mRNA along with daily oral MEKi treatment (Fig. 7C).